European Innovation Council

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Founded in 2016, SAALG Geomechanics specializes in real-time ground analysis software for civil works and building projects. It offers machine learning-driven solutions to anticipate ground movement issues, along with numerical models calibrations, soil parameter characterization, and geotechnical consulting services.

Founded in 2016, SAALG Geomechanics specializes in real-time ground analysis software for civil works and building projects. It offers machine learning-driven solutions to anticipate ground movement issues, along with numerical models calibrations, soil parameter characterization, and geotechnical consulting services.

Aortyx is a pioneering company founded by researchers from IQS School of Engineering and Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases, focusing on tissue regeneration through mimicking the aorta's biomechanical environment.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

X1 Wind is a company based in Barcelona, Spain, specializing in the development of innovative floating wind platforms for deep-water offshore wind energy. Founded in 2017, X1 Wind has engineered its platform to achieve a significant reduction in both cost and weight—by 50 percent and 80 percent, respectively—compared to traditional floating wind systems. The design features fewer active systems than current alternatives, allowing for simplified installation that can be completed at the port and transported to the site using a small tugboat. This approach not only enhances operational depth range but also improves scalability and reduces maintenance requirements. By focusing on these advancements, X1 Wind aims to provide a clean, affordable energy solution while contributing to global efforts to lower carbon emissions.

Unblur is a technology company that develops an incident command platform for public emergency services, providing real-time situational awareness and centralized data and tools to support incident commanders. Its modular SaaS platform, IRIS, is designed to coordinate responders, streamline decision-making, and improve operational response at all stages of an incident. Founded in 2015, Unblur is headquartered in Barcelona, Spain.

Unblur is a technology company that develops an incident command platform for public emergency services, providing real-time situational awareness and centralized data and tools to support incident commanders. Its modular SaaS platform, IRIS, is designed to coordinate responders, streamline decision-making, and improve operational response at all stages of an incident. Founded in 2015, Unblur is headquartered in Barcelona, Spain.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

AEInnova develops autonomous industrial monitoring devices for predictive maintenance. Its flagship device InduEye is battery-free, self-powered, and capable of edge computing for real-time vibration, thermal, and steam-trap monitoring, powered by waste heat with optional solar or wind energy. It uses LoRaWAN or NB-IoT/LTE-CAT M for communications and streams data to cloud dashboards with analytics, alarms, and environmental impact analysis. The system aims to reduce downtime and maintenance costs through non-invasive, self-sustaining monitoring. Certifications include CE and ATEX/IECEX, with FCC ongoing. The technology is deployed across sectors such as oil and gas, aluminium, steel, paper, rubber, water treatment, and energy, with customers including Repsol, Cepsa, ArcelorMittal, Enel, and others. AEInnova has been recognized as a leading EU scale-up with multiple awards and EC funding, and participates in EU R&D initiatives related to energy harvesting and high-temperature IoT.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

AEInnova develops autonomous industrial monitoring devices for predictive maintenance. Its flagship device InduEye is battery-free, self-powered, and capable of edge computing for real-time vibration, thermal, and steam-trap monitoring, powered by waste heat with optional solar or wind energy. It uses LoRaWAN or NB-IoT/LTE-CAT M for communications and streams data to cloud dashboards with analytics, alarms, and environmental impact analysis. The system aims to reduce downtime and maintenance costs through non-invasive, self-sustaining monitoring. Certifications include CE and ATEX/IECEX, with FCC ongoing. The technology is deployed across sectors such as oil and gas, aluminium, steel, paper, rubber, water treatment, and energy, with customers including Repsol, Cepsa, ArcelorMittal, Enel, and others. AEInnova has been recognized as a leading EU scale-up with multiple awards and EC funding, and participates in EU R&D initiatives related to energy harvesting and high-temperature IoT.

AEInnova develops autonomous industrial monitoring devices for predictive maintenance. Its flagship device InduEye is battery-free, self-powered, and capable of edge computing for real-time vibration, thermal, and steam-trap monitoring, powered by waste heat with optional solar or wind energy. It uses LoRaWAN or NB-IoT/LTE-CAT M for communications and streams data to cloud dashboards with analytics, alarms, and environmental impact analysis. The system aims to reduce downtime and maintenance costs through non-invasive, self-sustaining monitoring. Certifications include CE and ATEX/IECEX, with FCC ongoing. The technology is deployed across sectors such as oil and gas, aluminium, steel, paper, rubber, water treatment, and energy, with customers including Repsol, Cepsa, ArcelorMittal, Enel, and others. AEInnova has been recognized as a leading EU scale-up with multiple awards and EC funding, and participates in EU R&D initiatives related to energy harvesting and high-temperature IoT.

X1 Wind is a company based in Barcelona, Spain, specializing in the development of innovative floating wind platforms for deep-water offshore wind energy. Founded in 2017, X1 Wind has engineered its platform to achieve a significant reduction in both cost and weight—by 50 percent and 80 percent, respectively—compared to traditional floating wind systems. The design features fewer active systems than current alternatives, allowing for simplified installation that can be completed at the port and transported to the site using a small tugboat. This approach not only enhances operational depth range but also improves scalability and reduces maintenance requirements. By focusing on these advancements, X1 Wind aims to provide a clean, affordable energy solution while contributing to global efforts to lower carbon emissions.